Similar articles for PMID: 17256799

Year	Number of Results
2002	2
2003	5
2004	8
2005	5
2006	5
2007	13
2008	8
2009	15
2010	8
2011	3
2012	4
2013	6
2014	3
2015	5
2016	6
2017	4
2018	2
2019	2
2020	1
2021	1
2024	0

1

Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy.

Kim W, Pyeritz RE, Bernhardt BA, Casey M, Litt HI. Kim W, et al. Am J Med Genet A. 2007 Feb 15;143(4):377-81. doi: 10.1002/ajmg.a.31600. Am J Med Genet A. 2007. PMID: 17256799

2

Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.

Wang RY, Abe JT, Cohen AH, Wilcox WR. Wang RY, et al. J Inherit Metab Dis. 2008 Dec;31 Suppl 2:S369-74. doi: 10.1007/s10545-008-0930-x. Epub 2008 Oct 21. J Inherit Metab Dis. 2008. PMID: 18937048

3

Treatment with agalsidase beta during pregnancy in Fabry disease.

Politei JM. Politei JM. J Obstet Gynaecol Res. 2010 Apr;36(2):428-9. doi: 10.1111/j.1447-0756.2009.01164.x. J Obstet Gynaecol Res. 2010. PMID: 20492401

4

Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.

Ramaswami U, Bichet DG, Clarke LA, Dostalova G, Fainboim A, Fellgiebel A, Forcelini CM, An Haack K, Hopkin RJ, Mauer M, Najafian B, Scott CR, Shankar SP, Thurberg BL, Tøndel C, Tylki-Szymanska A, Bénichou B, Wijburg FA. Ramaswami U, et al. Mol Genet Metab. 2019 May;127(1):86-94. doi: 10.1016/j.ymgme.2019.03.010. Epub 2019 Apr 3. Mol Genet Metab. 2019. PMID: 30987917 Free article. Clinical Trial.

5

Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.

Senocak Tasci E, Bicik Z. Senocak Tasci E, et al. Iran J Kidney Dis. 2015 Sep;9(5):406-8. Iran J Kidney Dis. 2015. PMID: 26338166 Free article.

6

Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.

Mehta A, Beck M, Kampmann C, Frustaci A, Germain DP, Pastores GM, Sunder-Plassmann G. Mehta A, et al. Mol Genet Metab. 2008 Sep-Oct;95(1-2):114-5. doi: 10.1016/j.ymgme.2008.07.002. Epub 2008 Aug 12. Mol Genet Metab. 2008. PMID: 18701330 No abstract available.

7

Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.

Banikazemi M, Ullman T, Desnick RJ. Banikazemi M, et al. Mol Genet Metab. 2005 Aug;85(4):255-9. doi: 10.1016/j.ymgme.2005.04.009. Mol Genet Metab. 2005. PMID: 15939645

8

Agalsidase alfa: a review of its use in the management of Fabry disease.

Keating GM. Keating GM. BioDrugs. 2012 Oct 1;26(5):335-54. doi: 10.2165/11209690-000000000-00000. BioDrugs. 2012. PMID: 22946754 Review.

9

Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.

Wanner C. Wanner C. Int J Clin Pract. 2007 Jul;61(7):1234-5; author reply 1235. doi: 10.1111/j.1742-1241.2007.01399.x. Int J Clin Pract. 2007. PMID: 17577304 No abstract available.

10

Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.

Sasa H, Nagao M, Kino K. Sasa H, et al. Mol Genet Metab. 2019 Apr;126(4):448-459. doi: 10.1016/j.ymgme.2019.02.005. Epub 2019 Feb 20. Mol Genet Metab. 2019. PMID: 30803893 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

91 results

Results by year